Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC

NCT02072486 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02072486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02072486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC
Lead sponsor
Roswell Park Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
November 18, 2013
Completion date
July 19, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma, localized non-resectable adult hepatocellular carcinoma, stage iii childhood hepatocellular carcinoma, stage iiia hepatocellular carcinoma, stage iiib hepatocellular carcinoma, stage iiic hepatocellular carcinoma, stage iv childhood hepatocellular carcinoma, stage iva hepatocellular carcinoma, stage ivb hepatocellular carcinoma